UPDATE: Frequency Therapeutics to present newest FX-322 clinical trial results on September 17, 2019 [early]

Latest FX-322 study results… earlier than expected?

The upcoming presentation, “Phase 1/2 Hearing Loss Trial of Intratympanic FX322, a Progenitor Cell Activator,” was previously scheduled for September 18, 2019.

But according to the AAO-HNSF Annual Meeting website, the presentation date has been changed from September 18 to September 17.

Coming Sooner

Here is the updated schedule and a link to the page where this information can be found:

Title: Phase 1/2 Hearing Loss Trial of Intratympanic FX322, a Progenitor Cell Activator
Session: Late Breaking Scientific Oral Presentations
Location: Ernest N. Morial Convention Center, Room 286/287
Date: Tuesday, Sep 17 8:24 AM

Source:
https://plan.core-apps.com/aao2019/event/d29afee0ef623a96e8827526a952c271

Could the date of the presentation be changed again? It’s possible. But the conference takes place between September 15 – 18, 2019… so, any scheduling changes should still stay within that date range.

Check the front page of this site for more updates OR sign up for free email updates, which will be sent out once-a-week starting June 21. (Note from admin: I’m still setting up the newsletter system, it will be ready soon!)


Subscribe to Email Updates

Newsletter subscribers get early access to our latest articles. Expect 1 to 3 emails per week.

This field is for validation purposes and should be left unchanged.

No spam, no third parties, and 100% free. Your information is kept private. Unsubscribe with one click anytime.